New combo therapy hopes to boost lung cancer treatment

NCT ID NCT05937906

Recruiting now Disease control Sponsor: Centre Georges Francois Leclerc Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 05, 2026 · Updated 28 times

Summary

This study tests adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy for people with advanced non-squamous non-small cell lung cancer whose PDL1 is below 50%. The trial has two parts: first, finding the safest dose, then comparing the new combination to standard treatment in 24 participants. The goal is to see if this approach is safe and works better than current therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Georges-François Leclerc
RECRUITING

Dijon, Burgundy, 21000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER